New pill targets hard-to-treat cancers with specific gene changes

NCT ID NCT04521686

First seen May 03, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This early-phase study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, bone cancer, or brain tumors) that have certain IDH gene mutations. The main goals are to find the safest dose and see if the drug can shrink tumors or slow their growth. About 200 participants will receive the drug alone or with chemotherapy or immunotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Gustave Roussy

    Villejuif, 94805, France

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Indiana University School of Medicine

    Indianapolis, Indiana, 46202, United States

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, 33076, France

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, 241-8515, Japan

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Rochester, Minnesota, 55902, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic of Scottsdale

    Phoenix, Arizona, 85054, United States

  • Memorial Sloan Kettering Cancer Center

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Cancer Center

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng-Kung Uni. Hosp.

    Tainan, 704, Taiwan

  • National University Hospital

    Singapore, 669606, Singapore

  • Osaka University Hospital

    Suita-shi, Osaka, 565-0871, Japan

  • Prince of Wales Hospital

    Hong Kong, Shatin, New Territories, Hong Kong

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea

  • Sarah Cannon Cancer Center

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Shizuoka Cancer Center

    Nakatogari, Shizuoka, 411-8777, Japan

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas, 78229, United States

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • The John Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • The University of Arizona Cancer Center

    Tucson, Arizona, 85724, United States

  • USC Norris Cancer Hospital

    Los Angeles, California, 90033, United States

  • University of Chicago Pritzker School of Medicine

    Chicago, Illinois, 60637, United States

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.